SCHEMBL2207331

SCHEMBL2207331

OB(O)/C=C/Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 1.00
CA2 P00918 2/20 1.00
ARG2 P78540 1/20 1.00
MAOB P27338 1/20 0.61
TOP1 P11387 1/20 0.43
MGLL Q99685 1/20 0.41
TSHR P16473 2/20 0.39
CALM1 P0DP23 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
IDO1 P14902 3/20 0.34
THRB P10828 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
AKR1B1 P15121 1/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2207335 1.00 CA1 (1.00) CA1CA2ARG2MAOBTOP1
SCHEMBL9397700 0.78 MAOB (0.70) CA1CA2ARG2MAOBTOP1
SCHEMBL655670 0.78 MAOB (0.70) CA1CA2ARG2MAOBTOP1
SCHEMBL5165097 0.78 MAOB (0.70) CA1CA2ARG2MAOBTOP1
SCHEMBL1524697 0.77 MAOB (1.00) CA1CA2ARG2MAOBTOP1
SCHEMBL155055 0.77 MAOB (1.00) CA1CA2ARG2MAOBTOP1
SCHEMBL155054 0.77 MAOB (1.00) CA1CA2ARG2MAOBTOP1
SCHEMBL4157113 0.75 CA1 (0.60) CA1CA2ARG2MAOBMAPK1
SCHEMBL4157108 0.75 CA1 (0.60) CA1CA2ARG2MAOBMAPK1
SCHEMBL28437378 0.72 CA1 (0.57) CA1CA2ARG2MAOBTOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250288559-A1 PREP BINDING LIGANDS POLKU THERAPEUTICS OY (FI) 2025-09-18 US disclosed
EP-4514781-A1 PREP BINDING LIGANDS Polku Therapeutics OY (FI) 2025-03-05 EP disclosed
CN-119451944-A PREP binding ligands 珀尔库治疗有限公司 2025-02-14 CN disclosed
EP-4083091-B1 POLYMER ELECTROLYTE, AND LITHIUM ION BATTERY COMPRISING SAME ZHUHAI COSMX BATTERY CO LTD (CN) 2024-08-14 EP disclosed
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS VERNALIS (R&D) LTD (GB) 2024-05-09 US disclosed
CN-112805267-B Carboxamide and sulfonamide derivatives as TEAD modulators 豪夫迈·罗氏有限公司 2024-03-08 CN disclosed
EP-4277892-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2023-11-22 EP disclosed
WO-2023209191-A1 PREP BINDING LIGANDS UNIVERSITY OF HELSINKI (FI) 2023-11-02 WO disclosed
CN-116940552-A Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2023-10-24 CN disclosed
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 EP disclosed
EP-1991544-A2 SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS Transtech Pharma, Inc. (US) 2008-11-19 EP disclosed
WO-2008130970-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2008-10-30 WO disclosed
EP-1966164-A1 NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES Janssen Pharmaceutica, N.V. (BE) 2008-09-10 EP disclosed
US-20080096799-A1 COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION FORBES MEDI-TECH (RESEARCH), INC. (US) 2008-04-24 US disclosed
US-20080096799-A1 COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION FORBES MEDI-TECH (RESEARCH), INC. (US) 2008-04-24 US disclosed
US-20080096799-A1 COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION FORBES MEDI-TECH (RESEARCH), INC. (US) 2008-04-24 US disclosed
WO-2008031032-A2 COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION TRANSITION THERAPEUTICS INC. (CA) 2008-03-13 WO disclosed
US-20070191385-A1 Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors VTV THERAPEUTICS LLC 2007-08-16 US disclosed
WO-2007089857-A2 SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS TRANSTECH PHARMA, INC. (US) 2007-08-09 WO disclosed
WO-2007071646-A1 NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096799-A1 COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION PNLIP, CPT1A, CPT1B CA1 3893/4885CA2 4481/4885ARG2 552/4885
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BAX, BCL2A1 CA1 2391/4885CA2 1311/4885ARG2 661/4885
US-20070191385-A1 Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors PTP4A1, PTPRJ, PTP4A2 CA1 2345/4885CA2 564/4885ARG2 2114/4885
US-20250288559-A1 PREP BINDING LIGANDS PREP, ERAP2, CTSA CA1 3454/4885CA2 1662/4885ARG2 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.